{"url_path":"/sec/mygn/8-k/2026-06-04/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/899923/0000899923-26-000059-index.html","accession_number":"0000899923-26-000059","cik":"0000899923","ticker":"MYGN","issuer_name":"MYRIAD GENETICS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/899923/0000899923-26-000059-index.html","primary_entity_key":"0000899923","primary_entity_name":"MYRIAD GENETICS INC"},"word_count":334,"has_tables":true,"body_markdown":"ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers\n\nAs reported below in Item 5.07, Myriad Genetics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”), at which the Company's stockholders approved an amendment to the Company's Amended and Restated 2012 Employee Stock Purchase Plan (the \"Purchase Plan\"), to increase the number of shares authorized for issuance under the Purchase Plan by an additional 4,000,000 shares. A summary of the material terms of the Purchase Plan is set forth in the Company's definitive proxy statement for the Annual Meeting, which was filed with the Securities and Exchange Commission on April 14, 2026 (the “Proxy Statement”). A copy of the Purchase Plan is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\nAdditionally, at the Annual Meeting, the Company's stockholders approved the Company's 2026 Employee, Director and Consultant Equity Incentive Plan (the “2026 Plan”). The 2026 Plan provides for the issuance of 6,400,000 shares of Company common stock plus 2,063,567 shares of Company common stock that remained available for grant under the Company's 2017 Employee, Director and Consultant Equity Incentive Plan, as amended (the “2017 Plan”), as of the date of the Annual Meeting, and were rolled over and became available for issuance under the 2026 Plan, for a total of 8,463,567 shares. The share reserve under the 2026 Plan may also be increased by shares underlying awards granted under the 2017 Plan that are forfeited, expire, or are cancelled without the delivery of shares on or after the date of the Annual Meeting, up to a maximum of 8,659,575 shares. No future awards will be granted under the 2017 Plan.\n\nA summary of the material terms of the 2026 Plan is set forth in the Proxy Statement. A copy of the 2026 Plan is attached as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated herein by reference."}